Cited by 212Acute Myeloid Leukemia ResearchGlioma Diagnosis and TreatmentChromatin Remodeling and Cancer

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML

Chaturvedi, Anuhar, Araujo Cruz, Michelle Maria, Jyotsana, Nidhi, Sharma, Amit, Yun, Haiyang, Görlich, Kerstin, Wichmann, Martin, Schwarzer, Adrian, Preller, Matthias, Thol, Felicitas, Meyer, Johann, Haemmerle, Reinhard, Struys, Eduard A., Jansen, Erwin E., Modlich, Ute, Li, Zhixiong, Sly, Laura M., Geffers, Robert, Lindner, Robert, Manstein, Dietmar J., Lehmann, Ulrich, Krauter, Jürgen, Ganser, Arnold, Heuser, Michael·2013·Blood

DOI 10.1182/blood-2013-03-491571

Open this paper in CoChat — free account

Abstract

Key Points: IDH1 promotes leukemogenesis in vivo in cooperation with HoxA9. Pharmacologic inhibition of mutant IDH1 efficiently inhibits AML cells of IDH1-mutated patients but not of normal CD34+ bone marrow cells.

Integrity signals

Registry

Crossref · 10.1182/blood-2013-03-491571

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Comparative Protein Modelling by Satisfaction of Spatial Restraints
Šali, A., & Blundell, T. L. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1626 · Cited by 12,977
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020

Show all 45 references

Research works printed but not linked: 1

Irwin, ZINC: a free tool to discover chemistry for biology [published online ahead of print June 15, 2012]., J Chem Inf Model

Sorted by citations

Items 101–200 of 212

Enigmas of IDH mutations in hematology/oncology
Heuser, M., Cruz, M. M. A., Goparaju, R., & Chaturvedi, A. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.005 · Cited by 28
Self-citation
DNA Methylation of T Lymphocytes as a Therapeutic Target: Implications for Rheumatoid Arthritis Etiology
Zhao, J., Wei, K., Chang, C., Xu, L., Jiang, P., Guo, S., Schrodi, S. J., & He, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.863703 · Cited by 30
Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila
Reitman, Z. J., Sinenko, S. A., Spana, E. P., & Yan, H. (2014) · Blood · doi:10.1182/blood-2014-05-577940 · Cited by 29
Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia
Yun, H., Damm, F., Yap, D., Schwarzer, A., Chaturvedi, A., Jyotsana, N., Lübbert, M., Bullinger, L., Döhner, K., Geffers, R., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.101386 · Cited by 26
Self-citation
High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis
Kao, H., Liang, D., Kuo, M., Wu, J., Dunn, P., Wang, P., Lin, T., Shih, Y., Liang, S., Lin, T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5202 · Cited by 26
“recently reported that an inhibitor targeting mutant IDH1 induced apoptosis and decreased colony formation in methylcellulose of IDH1-mutant human primary bone marrow cells [33].”
Background
Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer
Chávez‐González, A., Bakhshinejad, B., Pakravan, K., Guzmán, M. L., & Babashah, S. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0297-1 · Cited by 26
“Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are frequently mutated in AML cells, thereby inducing global changes in DNAmethylation [83].”
IDH1/2 mutations in acute myeloid leukemia
Byun, J. M., Yoo, S.-J., Kim, H. J., Ahn, J., Koh, Y., Jang, J. H., & Yoon, S. (2022) · Blood Research · doi:10.5045/br.2021.2021152 · Cited by 33
“Due to increased reactive oxygen species (ROS) levels, genes associated with MAPK signaling are highly enriched in IDH1 mutant cells and transcription of cyclin-dependent kinase (CDK) inhibitors are repressed, leading to enhanced cell proliferation [40].”
Background
Novel epigenetic therapies in hematological malignancies: Current status and beyond
Gallipoli, P., & Huntly, B. J. P. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.005 · Cited by 25
“Similar findings were also shown in a retroviral transduction/transplantation mouse model [69].”
BackgroundResult
Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias
Testa, U., Castelli, G., & Pelosi, E. (2020) · Cancers · doi:10.3390/cancers12092427 · Cited by 26
“Other studies have supported a role of Meis1 and HoxA9 in cooperation with IDH1 or IDH2 mutant to drive leukemia development in mouse models.”
Background
Mutant IDH : A Targetable Driver of Leukemic Phenotypes Linking Metabolism, Epigenetics and Transcriptional Regulation
Garrett-Bakelman, F. E., & Melnick, A. M. (2016) · Epigenomics · doi:10.2217/epi-2016-0008 · Cited by 25
Epigenetic Changes as a Target in Aging Haematopoietic Stem Cells and Age-Related Malignancies
Buisman, S. C., & de Haan, G. (2019) · Cells · doi:10.3390/cells8080868 · Cited by 24
The molecular basis of myeloid malignancies
Kitamura, T., Inoue, D., Okochi, N., Kato, N., Komeno, Y., Yang, L. U., Enomoto, Y., Doki, N., UCHIDA, T., Kagiyama, Y., et al. (2014) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.90.389 · Cited by 26
Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic
Al-Hussaini, M., & DiPersio, J. F. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.932687 · Cited by 26
“demonstrated suppression of growth and MAPK signaling in IDH1-mutant leukemic cells when treated with HMS-101 (a SMI of IDH1 mutation) [357].”
Background
Targeting IDH: the next big thing in AML
Levis, M. J. (2013) · Blood · doi:10.1182/blood-2013-09-522441 · Cited by 23
“In this issue of Blood, Chaturvedi and coworkers use a small molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) to reverse the myeloproliferative effects induced by the “oncometabolite” 2-hydroxyglutarate (2-HG).(1)”
Impact of DNA methylation programming on normal and pre-leukemic hematopoiesis
Langstein, J., Milsom, M. D., & Lipka, D. B. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.008 · Cited by 25
“However, overexpression of mutant IDH1/2 in primary bone marrow cells does not lead to full malignant transformation of HSCs but rather disturbs hematopoietic differentiation and leads to elevated numbers of stem and progenitor cells [168, 173].”
Background
In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site
Chaturvedi, A., Goparaju, R., Gupta, C., Weder, J., Klünemann, T., Cruz, M. M. A., Kloos, A., Görlich, K., Schottmann, R., Othman, B., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0582-x · Cited by 25
Self-citation
Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia
Goswami, M., & Hourigan, C. S. (2015) · Current Drug Targets · doi:10.2174/1389450116666150223120005 · Cited by 23
Thioredoxin reductase is a major regulator of metabolism in leukemia cells
Karunanithi, S., Liu, R., Hou, Y., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01924-0 · Cited by 22
“Isocitrate dehydrogenase (IDH) inhibitors for IDH mutant AML patients for example have been a successful strategy to target metabolism in AML [5, 6].”
Background
CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia
He, L., Arnold, C., Thoma, J., Rohde, C., Kholmatov, M. M., Garg, S., Hsiao, C., Viol, L., Zhang, K., Sun, R., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114990 · Cited by 20
Assessing acquired resistance to IDH1 inhibitor therapy by full-exon IDH1 sequencing and structural modelingPreprint
Oltvai, Z. N., Harley, S. E., Koes, D. R., Michel, S. N., Warlick, E. D., Nelson, A., Yohe, S. L., & Mroz, P. (2021) · Molecular Case Studies · doi:10.1101/mcs.a006007 · Cited by 24
“Targeted inhibition of pathogenic IDH1/2 variants has been shown to reduce the production of 2-HG and decrease leukemic burden (Chaturvedi et al. 2013; Wang et al. 2013; Upadhyay et al. 2017; Yen et al. 2017).”
Background
The genetics of myelodysplastic syndromes and the opportunities for tailored treatments
Kontandreopoulou, C., Kalopisis, K., Viniou, N., & Diamantopoulos, P. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.989483 · Cited by 23
IDH1 -Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation
Landberg, N., Köhnke, T., Feng, Y., Nakauchi, Y., Fan, A. C., Linde, M. H., Karigane, D., Lim, K. S., Sinha, R., Malcovati, L., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0195 · Cited by 23
Mitochondrial metabolic remodeling in response to genetic and environmental perturbations
Hollinshead, K. E. R., & Tennant, D. A. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1334 · Cited by 22
Identification of COX5B as a novel biomarker in high-grade glioma patients
Hu, T., & Xi, J. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s139243 · Cited by 21
“Among these, glioblastoma (GBM) is the most common and most aggressive cancer, and represents 15% of brain tumors.(8,9) There is no clear way to prevent the disease.”
Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors
Zheng, Q., Tang, S., Fu, X., Chen, Z., Ye, Y., Lan, X., Jiang, L., Huang, Y., Ding, J., Geng, M., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.10.029 · Cited by 20
Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice
Mylonas, E., Janin, M., Bawa, O., Opolon, P., David, M. D., Quivoron, C., Bernard, O., Ottolenghi, C., Debotton, S., & Penard‐Lacronique, V. (2014) · Leukemia · doi:10.1038/leu.2014.18 · Cited by 20
The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor
Eskandari, M. R., Shi, Y., Liu, J., Albanese, J. M., Goel, S., Verma, A. K., & Wang, Y. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1817441 · Cited by 19
“Therefore, small molecules that target enzymes or receptors involving different signal transduction pathways have been developed, some have been used in clinical trials [38,39].”
Method
Distinct Histopathologic and Molecular Alterations in Inflammatory Bowel Disease-Associated Intestinal Adenocarcinoma: c-MYC Amplification is Common and Associated with Mucinous/Signet Ring Cell Differentiation
Hartman, D. J., Binion, D. G., Regueiro, M. D., Miller, C., Herbst, C., & Pai, R. K. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy057 · Cited by 18
Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia
Kloos, A., Mintzas, K., Winckler, L., Gabdoulline, R. R., Alwie, Y., Jyotsana, N., Kattre, N., Schottmann, R., Scherr, M., Gupta, C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0929-3 · Cited by 18
“The size of the animal cohorts was based on our previous study [34, 35].”
MethodSelf-citation
Understanding and Targeting Metabolic Vulnerabilities in Acute Myeloid Leukemia: An Updated Comprehensive Review
Addanki, S., Kim, L. E., & Stevens, A. M. (2025) · Cancers · doi:10.3390/cancers17081355 · Cited by 18
“…phosphorylation, induces apoptosis in pediatric AML cells, and prolongs survival in pediatric AML xenografts IDH1 mutations have been shown to accelerate the onset of myeloid leukemia-like disease in mice, and they interact with HoxA9, resulting in accelerated cell cycle progression [174].”
Novel strategies to prevent relapse after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes
Kekre, N. K., & Koreth, J. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000116 · Cited by 17
“RAS and IDH1 represent targets for other small molecule inhibitors that have shown antileukaemic activity in the preclinical setting [39,40].”
Background
Metabolomic comparison between cells over‐expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism
Wen, H., Cho, H. R., Yun, T., Kim, H., Park, C., Lee, S., Choi, S. H., & Park, S. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12950 · Cited by 20
“Recently, another inhibitor developed against the IDH1 mutant inhibited the colony formation of AML cells derived from patients (Chaturvedi et al. 2013).”
Background
Acute myeloid leukemia: advancing clinical trials and promising therapeutics
Daver, N. G., Cortes, J. E., Kantarjian, H. M., & Ravandi, F. (2016) · Expert Review of Hematology · doi:10.1586/17474086.2016.1158096 · Cited by 16
“Chaturvedi et al demonstrated that a small molecule inhibitor of mutant IDH1 successfully reversed the myeloproliferative effects induced by the oncometabolite 2hydroxyglutarate (105).”
Background
Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors
Liu, X., Hu, Y., Gao, A., Xu, M., Gao, L., Xu, L., Zhou, Y., Gao, J., Ye, Q., & Li, J. X. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.12.029 · Cited by 16
Pyridine Moiety: Recent Advances in Cancer Treatment
Sahu, R., Mishra, R., Kumar, R., Majee, C., Salahuddin, S., MAZUMDER, A., & Kumar, A. (2021) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.763 · Cited by 16
“Pharmacological barrier of mutant IDH1 enzyme efficiently inhibits colony formation of IDH mutated patient derived AML cells but not that of normal CD34+ (cluster of differentiation 34 which is a glycosylated transmembrane protein) bone marrow cells[77].”
Background
PIWI-interacting RNAs (PiRNAs) as emerging biomarkers and therapeutic targets in biliary tract cancers: A comprehensive review
Asouri, S. A., Aghadavod, E., Mirzaei, H., Abaspour, A., & Shahaboddin, M. E. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33767 · Cited by 17
New Insights in AML Biology From Genomic Analysis
Perry, A. M., & Attar, E. C. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.08.005 · Cited by 15
Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas
Romanidou, O., Kotoula, V., & Fountzilas, G. (2018) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20101 · Cited by 15
Differentiation Therapy
Chen, S., Yan, X., Zhou, G., & Chen, Z. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm011 · Cited by 15
Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors
Kitagawa, Y., Kobayashi, A., Cahill, D. P., Wakimoto, H., & Tanaka, S. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189102 · Cited by 13
2‐Hydoxyglutarate: D/Riving Pathology in gLiomaS
Wahl, D. R., & Venneti, S. (2015) · Brain Pathology · doi:10.1111/bpa.12309 · Cited by 14
“Pharmacologic inhibitors of mutant IDH1 and IDH2 have been recently synthesized and show great promise in cell lines, IDH 1/2 tumor animal models and AML patients (17, 42, 54, 73, 74, 94).”
Background
Molecular Genetic Biomarkers in Myeloid Malignancies
Matynia, A. P., Szankasi, P., Shen, W., & Kelley, T. W. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0096-ra · Cited by 15
D-2-hydroxyglutarate supports a tolerogenic phenotype with lowered major histocompatibility class II expression in non-malignant dendritic cells and acute myeloid leukemia cells
Hammon, K., Renner, K., Althammer, M., Voll, F., Babl, N., Decking, S.-M., Siska, P. J., Matos, C., Cárdenas-Conejo, Z. E., Mendes, K., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.283597 · Cited by 16
“10 In contrast, it has been shown by others that D-2-HG, but not its L-enantiomer, is sufficient to promote leukemogenesis in a human and murine cell-based model.”
Therapeutic targeting of chromatin alterations in leukemia and solid tumors
Perner, F., Berg, T., Sasca, D., Mersiowsky, S., Gadrey, J. Y., Thomas, J. M., Kühn, M. W. M., & Lübbert, M. (2025) · International Journal of Cancer · doi:10.1002/ijc.35389 · Cited by 16
“182 These actions preferentially preserve the survival of IDH-mutated cancer cells.”
Association between mutant IDHs and tumorigenesis in gliomas
Ohba, S., & Hirose, Y. (2018) · Medical Molecular Morphology · doi:10.1007/s00795-018-0189-8 · Cited by 15
Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations
Li, B., Mascarenhas, J. O., & Rampal, R. K. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0491-5 · Cited by 13
Cytosine modifications in myeloid malignancies
Meldi, K. M., & Figueroa, M. E. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.002 · Cited by 13
Economic impact of genomic diagnostics for intermediate‐risk acute myeloid leukaemia
Cressman, S., Karsan, A., Hogge, D. E., McPherson, E., Bolbocean, C., Regier, D. A., & Peacock, S. J. (2016) · British Journal of Haematology · doi:10.1111/bjh.14076 · Cited by 12
Altered Metabolism of Leukemic Cells: New Therapeutic Opportunity
Starková, J., Heřmanová, I., Hložková, K., Hararova, A., & Trka, J. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.07.012 · Cited by 13
Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility
Hou, H., & Tien, H. (2016) · Expert Review of Hematology · doi:10.1586/17474086.2016.1144469 · Cited by 13
“Interestingly, co-expressing mutant IDH1 and Hoxa9 could greatly accelerate the onset of MPN via repression of cyclindependent kinase inhibitors and activation of mitogenactivated protein kinase signaling [51].”
Background
Genetic mutations in acute myeloid leukemia that influence clinical decisions
Chung, S. S. (2014) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000024 · Cited by 10
Cancer Stem Cells as a Target Population for Drug Discovery
Bouvard, C., Barefield, C., & Zhu, S. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.106 · Cited by 10
The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches
Gruber, E., & Kats, L. M. (2023) · Biochemical Society Transactions · doi:10.1042/bst20230017 · Cited by 11
Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies
Okosun, J., Packham, G., & Fitzgibbon, J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.923402 · Cited by 12
“Retroviral transduction of IDH mutations in combination with additional oncogenes (HOXA9, FLT3 or NRAS) into primary mouse bone marrow cells followed by transplantation were shown to be sufficient to drive leukaemia development [62-64].”
Background
Induction chemotherapy in acute myeloid leukaemia: origins and emerging directions
Upadhyay, V. A., & Fathi, A. T. (2018) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000407 · Cited by 10
3‐(7‐Azaindolyl)‐4‐indolylmaleimides as a novel class of mutant isocitrate dehydrogenase‐1 inhibitors: Design, synthesis, and biological evaluation
Hu, Y., Gao, A., Liao, H., Zhang, M., Xu, G., Gao, L., Xu, L., Zhou, Y., Gao, J., Ye, Q., et al. (2018) · Archiv der Pharmazie · doi:10.1002/ardp.201800039 · Cited by 10
Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors
Tecik, M., & Adan, A. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01202-7 · Cited by 9
“Mutant IDH1 leads to suppression of CDKN2A and CDKN2B stimulating MAPK pathway and results in enhanced cell proliferation [176, 184].”
Background
Mechanism analysis and targeted therapy of IDH gene mutation in glioma
Ma, X. (2025) · American Journal of Cancer Research · doi:10.62347/nsxc2205 · Cited by 10
Dysregulation of HOXA genes in acute myeloid leukemia and targeted therapy
Huang, W., Zhang, F., Zhang, Z., Wang, Q., & Chen, S. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01200-4 · Cited by 9
“Additionally, by altering DNA methylation patterns, epigenetic modi ﬁ ers (DNMT3A mutations and IDH1/2 mutations) can change the expression of HOXA 76,77 .”
IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies
Bray, A., & Sahai, V. (2025) · Current Oncology · doi:10.3390/curroncol32010044 · Cited by 9
Epigenetic deregulation in myeloid malignancies
Meldi, K. M., & Figueroa, M. E. (2014) · Translational research · doi:10.1016/j.trsl.2014.04.012 · Cited by 9
Metabolic Reprogramming and Cell Adhesion in Acute Leukemia Adaptation to the CNS Niche
Sharma, N. D., Keewan, E. F., & Matlawska‐Wasowska, K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.767510 · Cited by 8
“In the TCA cycle, isocitrate dehydrogenase (IDH) (Chaturvedi et al., 2013) catalyzes the reversible conversion of isocitrate to alphaketoglutarate (α-KG) (Haselbeck and McAlister-Henn, 1993).”
BackgroundInfluential
Molecular Analysis of Gene Rearrangements and Mutations in Acute Leukemias and Myeloid Neoplasms
Sholl, L., Longtine, J., & Kuo, F. C. (2017) · Current Protocols in Human Genetics · doi:10.1002/cphg.31 · Cited by 4
“IDH1 and IDH2 mutations, for example, are targets for promising new therapeutics for acute leukemias (Chaturvedi et al., 2013).”
Background
Novel working hypothesis for pathogenesis of hematological malignancies: combination of mutations-induced cellular phenotypes determines the disease (cMIP-DD)
Kitamura, T., Watanabe‐Okochi, N., Enomoto, Y., Nakahara, F., Oki, T., Komeno, Y., Kato, N., Doki, N., Uchida, T., Kagiyama, Y., et al. (2015) · The Journal of Biochemistry · doi:10.1093/jb/mvv114 · Cited by 7
Isocitrate Dehydrogenase Mutations in Human Cancers: Physiopathologic Mechanisms and Therapeutic Targeting
malignancy, A. I. A. H. H., mutations, C. B. T. A. O. V. S. G. A. A. O. I. M. C. A. A. V. S. O. M. S. C. O. I. T. L. 2. D. H. L. T. T. I. O. T. B. T. O. G., (HPCs), W. C. T. S. D. O. T. L. P. T. C. I. M. C. A. S. A. T. H. S. C. (. A. P. C., in, S. A. T. M., of, T. L., in, O. T. M., HPCs, R. T. K. T. C. I. M. P. S.-R. A. B. T. D. O., involving, S. A. T. T. F., & involving, O. T. T. F. (2016) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2016.00019 · Cited by 8
Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML
Kingsley, M. C., Xie, H. M., Chen, B.-R., Riedel, S. S., Pastuer, T., Bollig, M. K., Shank, T., Libbrecht, C., Stabler, S. P., Deshpande, A. J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001922 · Cited by 6
“increases penetrance and accelerates leukemia when combined with retroviral overexpression of HOXA9, a critical downstream mediator of the oncogenic effect of KMT2A rearrangements.(38) Therefore, both oncogenes have a track record of reading out in vivo cooperation when used in a murine retroviral overexpression model.”
Background
MAGPEL: an autoMated pipeline for inferring vAriant-driven Gene PanEls from the full-length biomedical literature
Saberian, N., Shafi, A., Peyvandipour, A., & Drăghici, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-68649-0 · Cited by 6
Mouse Models of Frequently Mutated Genes in Acute Myeloid Leukemia
Mohanty, S., & Heuser, M. (2021) · Cancers · doi:10.3390/cancers13246192 · Cited by 6
“Retroviral overexpression of the hotspot DNMT3A-Arg882His (R882H) mutation induces CMML in mice (Table 1; Supplementary Figure S1) [55].”
BackgroundInfluentialSelf-citation
Mouse Models of Myeloid MalignanciesPreprint
Basheer, F., & Vassiliou, G. S. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a035535 · Cited by 6
Reviewing the IDH1 Mutation‐Mediated Mechanism of Drug Resistance and Revisiting Its Overcoming Strategies
Wang, Y., Bai, H., Wang, A., Zhao, J., Guo, H., Tang, Y., Wang, Y., & Xie, Q. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70102 · Cited by 6
IDH1 Mutation Impacts DNA Repair Through ALKBH2 Rendering Glioblastoma Cells Sensitive to Artesunate
Switzeny, O. J., Pusch, S., Christmann, M., & Kaina, B. (2025) · Biomedicines · doi:10.3390/biomedicines13061479 · Cited by 4
Combination therapy involving azacitidine for acute myeloid leukemia patients ineligible for intensive chemotherapy
Li, J., Fu, S., Ye, C., & Li, J. (2024) · Leukemia Research · doi:10.1016/j.leukres.2024.107638 · Cited by 4
mIDH-associated DNA hypermethylation in acute myeloid leukemia reflects differentiation blockage rather than inhibition of TET-mediated demethylation
Wiehle, L., Raddatz, G., Pusch, S., Gutekunst, J., von Deimling, A., Rodríguez‐Paredes, M., & Lyko, F. (2017) · Cell Stress · doi:10.15698/cst2017.10.106 · Cited by 4
“In human AML and lower-grade glioma, global pathogenic DNA hypermethylation has been associated with the presence of mIDH [10, 13-20].”
Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation
Heiblig, M., Khalife‐Hachem, S., Willekens, C., Micol, J., Paci, A., Penard‐Lacronique, V., & de Botton, S. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1831909 · Cited by 4
DNA Methylation Alterations in Acute Myeloid Leukemia: Therapeutic Potential
Adan, A. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_192 · Cited by 4
Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation
Pasquier, F., Chahine, C., Marzac, C., & de Botton, S. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1792286 · Cited by 3
Relation between tumor micro-environment and epigenetic alterations in hematological malignancies
Torres, X., & Cómbita, A. L. (2021) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2021.100024 · Cited by 3
The ubiquitin ligase Triad1 influences myeloid leukemogenesis by regulating the integrated stress response
Wang, H., Suh, F., Fischietti, M., et al. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110484 · Cited by 2
“Gcn1-stabilization increased translation of anti-apoptotic proteins Bcl6 and Nfkb2, signal modulators Stat5a and Shp1, and the emergency gran-ulopoiesis mediator IL1R but decreased translation of Cas-pases, Fanconi DNA repair proteins, and leukemia suppressors Ezh2 and Idh1 ((13, 41–43)).”
Approaches to Autoimmune Diseases Using Epigenetic Therapy
Hedrich, C. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812215-0.00013-3 · Cited by 2
Cancer Biomarkers in the Era of Systems Biology
Firdous, S., Srivastava, S. K., & Saha, S. (2022) · Springer eBooks · doi:10.1007/978-981-19-1953-4_3 · Cited by 1
Genetic and Epigenetic Profiling in Personalized Medicine: Advances in Treatment of Acute Myeloid Leukemia
Pavlović, S., & Tos̆ić, N. (2019) · Europeanization and globalization · doi:10.1007/978-3-030-16465-2_28 · Cited by 1
Adoptive cell therapy in acute myeloid leukemia: the current landscape and emerging strategies
Tharakan, S., Tremblay, D. A., & Azzi, J. M. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2414112 · Cited by 1
“Other AMl-specific mutations such as mutated IDH1 are also predominantly intracellular and thus difficult to target via cAR therapies [14–16].”
A patent review of IDH1 inhibitors (2018-present)
Liang, Q., Wen, F., Wang, P., Jiang, Y., Geng, Y., & Zha, X. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2500959 · Cited by 1
Targeted Therapy of IDH1-Mutated Tumors
Clark, O., & Grommes, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-49864-5_10 · Cited by 1
Pharmacoepigenetics of Systemic Lupus Erythematosus
Hedrich, C. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813939-4.00021-8 · Cited by 1
Cancer Metabolism
Wahl, D. R., & Venneti, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-61401-4_6 · Cited by 1
“Multiomics in precision medicine”
Katsos, K., Dhar, A., & Moinuddin, F. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13963-5.00011-x · Cited by 1
miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting
Xu, Y., Li, D., Wang, N., Ge, B., Chen, M., Zhao, M., Lin, Z., Li, M., Yuan, Y., Yue, C., et al. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01823-1 · Cited by 1
“Mutant IDH produces 2-hydroxyglutarate (2HG), which induces DNA hypermethylation [39, 40].”
Hematopoietic Stem Cells and Control of Hematopoiesis
Essawy, M., Abdelfattah‐Hassan, A., Radwan, E., Abdelhai, M. F., Elshaboury, S. S., & El‐Badri, N. (2020) · Learning materials in biosciences · doi:10.1007/978-3-030-55359-3_3 · Cited by 1
Future Developments: Novel Agents
Chua, C. C., & Wei, A. H. (2021) · Hematologic malignancies · doi:10.1007/978-3-030-72676-8_17 · Cited by 1
Acute Myeloid Leukemia in Adults: Mast Cell Leukemia and Other Mast Cell Neoplasms
Stone, R. M., & Schiffer, C. A. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm115 · Cited by 1
Neue Entwicklungen in der Therapie maligner hämatologischer Erkrankungen
Appelmann, I., & Brümmendorf, T. H. (2014) · Forum · doi:10.1007/s12312-014-1159-2
Genetic prognostic factors in acute myeloid leukemia
Erdei, A., Vellai, T., Andrikovics, H., & Váradi, A. (2014)
[Isocitrate dehydrogenase mutation in acute myeloid leukemia].
Zhang, Y., & Yang, L. (2015) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2015.01.023
“[23] Chaturvedi A, Araujo Cruz MM, Jyotsana N, et al.”
Background
[Modification of DNA methylation in leukemia development].
Gao, A., Zheng, Y., & Cheng, T. (2016) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2016.11.017
“[37] Chaturvedi A, Araujo CMM, Jyotsana N, et al.”
Background
Estudo da expressão dos genes TETs e níveis de hidroximetilação em meduloblastoma
Salomão, K. B. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2018.tde-18042018-104554
Acute Myeloid Leukemia: Mutations Blocking Differentiation Lead to Distinct Leukemic Subtypes
Cummings, A. L., Pan, D., & Schiller, G. J. (2019) · Springer eBooks · doi:10.1007/978-981-13-2977-7_15
Therapy-Induced Marrow Changes
Bhargava, P., & Whitman, J. D. (2020) · Springer eBooks · doi:10.1007/978-3-030-32189-5_32
Text Mining Of Variant-Genotype-Phenotype Associations From Biomedical Literature
Saberian, N. (2020) · Human Biology
Differentiation Therapy
Chen, S., Yan, X., Zhou, G., & Zhu, C. H. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm011.pub2

Authors: Chaturvedi, A., Araujo Cruz, M. M., Jyotsana, N., Sharma, A., Yun, H., Görlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F., Meyer, J., Haemmerle, R., Struys, E. A., Jansen, E. E., Modlich, U., Li, Z., Sly, L. M., Geffers, R., Lindner, R., Manstein, D. J., Lehmann, U., Krauter, J., Ganser, A., & Heuser, M.
Affiliations: Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation,
Institute of Experimental Hematology, and
Medizinische Hochschule Hannover (DE)
Vrije Universiteit Amsterdam (NL)
University of British Columbia (CA)
Helmholtz Centre for Infection Research (DE)
Institute of Cell Biology (UA)
ORCID: Chaturvedi, Anuhar
Jyotsana, Nidhi
Sharma, Amit
Yun, Haiyang
Schwarzer, Adrian
Preller, Matthias
Thol, Felicitas
Meyer, Johann
Struys, Eduard A.
Modlich, Ute
Li, Zhixiong
Sly, Laura M.
Geffers, Robert
Lindner, Robert
Manstein, Dietmar J.
Lehmann, Ulrich
Ganser, Arnold
Heuser, Michael
Venue: Blood
Publisher: American Society of Hematology
Published: 2013-10-17
Volume: 122
Issue: 16
Pages: 2877-2887
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2013-03-491571
OpenAlex: W2071370702
Cited by: 210
References: 45
Citations by year: 2026: 2 · 2025: 14 · 2024: 9 · 2023: 7 · 2022: 8 · 2021: 15 · 2020: 18 · 2019: 14 · 2018: 19 · 2017: 23 · 2016: 18 · 2015: 26 · 2014: 35 · 2013: 2
FWCI: 19.37
Type: journal article
Language: en
Open access: closed
Locations: Blood (publishedVersion)
PubMed (publishedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
Pure Amsterdam UMC (submittedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: IDH1 mutation, isocitrate dehydrogenase, acute myeloid leukemia, leukemogenesis, 2-hydroxyglutarate, HOXA9, myeloproliferative neoplasms, CDKN2A, CDKN2B, MAPK signaling, IDH1 inhibitor, therapeutic target
MeSH terms: Adolescent, Adult, Animals, Cell Cycle, Female, Humans, Isocitrate Dehydrogenase, Mice, Inbred C57BL, Middle Aged, Mutation, Leukemia, Myeloid, Acute, Gene Expression Regulation, Leukemic, Bone Marrow Transplantation, Apoptosis, Antigens, CD34, MAP Kinase Signaling System, Mice, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks